Go Deep
Bal Pharma Limited
Bal Pharma Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 21,432 | 23.1 | 2.03 | 1.94 | 104.77 |
| Sep 2026 | 21,432 | 23.1 | 2.03 | 1.94 | 104.77 |
| Sep 2026 | 21,432 | 23.1 | 2.03 | 1.94 | 104.77 |
| Oct 2026 | 20,495 | 23.3 | 2.05 | 1.94 | 105.74 |
| Oct 2026 | 20,470 | 20.5 | 1.80 | 1.94 | 93.06 |
Bal Pharma Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 886,161,000.0 | 840,757,000.0 | 876,897,000.0 | 740,249,000.0 |
| Net Profit | 11,235,000.0 | 35,935,000.0 | 17,799,000.0 | 7,095,000.0 |
| EPS | 0.7 | 2.3 | 1.1 | 0.5 |
Bal Pharma Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 3,029,791,000.0 | 2,942,731,000.0 | 3,392,196,000.0 | 3,017,073,000.0 | — |
| Net Profit | 62,836,000.0 | 72,154,000.0 | 73,922,000.0 | 25,717,000.0 | — |
| EPS | 4.0 | 4.6 | 5.0 | 1.7 | — |
Bal Pharma Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 3,755,398,000.0 | 3,356,903,000.0 | 3,198,383,000.0 | 3,131,723,000.0 | — |
| Total Liabilities | 2,932,873,000.0 | 2,582,859,000.0 | 2,478,668,000.0 | 2,494,701,000.0 | — |
| Total Equity | 822,275,000.0 | 774,159,000.0 | 720,044,000.0 | 637,891,000.0 | — |
Owes vs Owns
Bal Pharma Limited owed ₹0.78 for every ₹1 it owned in Mar 2026, down from ₹0.80 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.78× | 0.77× | 0.77× | 0.80× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Bal Pharma Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 2.5%Receivables 24.9%Inventory 31.0%Fixed assets (tangible) 22.7%Intangible assets 4.6%Long-term investments 1.4%Other assets 12.9%
How it's funded — Mar 2026
Short-term debt 34.0%Long-term debt 8.5%Payables 23.7%Other liabilities 11.9%Shareholders' equity 21.9%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 9.2 | 10.4 | 19.9 | 7.5 |
| Receivables | 93.6 | 92.4 | 99.6 | 94.0 |
| Inventory | 116.4 | 103.0 | 87.8 | 98.0 |
| Fixed assets (tangible) | 85.2 | 75.4 | 67.0 | 64.2 |
| Intangible assets | 17.2 | 15.8 | 15.2 | 14.3 |
| Long-term investments | 5.2 | 4.2 | 0.3 | 1.4 |
| Other assets | 48.6 | 34.4 | 30.0 | 33.8 |
| Liabilities & equity | ||||
| Short-term debt | 127.6 | 119.0 | 103.2 | 100.5 |
| Long-term debt | 31.9 | 31.4 | 36.3 | 30.5 |
| Payables | 89.0 | 81.7 | 77.5 | 78.9 |
| Other liabilities | 44.8 | 26.2 | 30.8 | 39.5 |
| Shareholders' equity | 82.3 | 77.4 | 72.0 | 63.7 |
| Net tangible assets | 65.0 | 61.6 | 56.8 | 49.5 |
Bal Pharma Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 308,354,000.0 | 203,151,000.0 | 228,058,000.0 | -15,371,000.0 | — |
| Investing Activities | -206,994,000.0 | -149,169,000.0 | -188,909,000.0 | -221,824,000.0 | — |
| Financing Activities | -95,864,000.0 | -78,424,000.0 | -12,063,000.0 | 240,938,000.0 | — |